Okay, I will analyse the provided text and verify the claims made within it using web searches.Here’s a breakdown of the data, with verification and notes. I will focus on dates and key facts to ensure accuracy.
Overall Summary of the Text:
The text discusses tabelecleucel (tab-cel), a treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients who have failed prior rituximab or rituximab + chemotherapy. It summarizes findings from a Phase 3 clinical trial (ALLELE) and regulatory updates from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals.
Verification of Claims & Details:
- FDA Acceptance & Priority Review:
* Claim: The FDA accepted and granted priority review to the biologics license request (BLA) for tabelecleucel.
* Verification: Multiple sources confirm this.
* https://www.atarabio.com/news-releases/news-release-details/atara-biotherapeutics-announces-us-fda-acceptance-and (July 17, 2024 – matches text)
* https://www.pierre-fabre.com/en/newsroom/press-releases/pierre-fabre-pharmaceuticals-inc-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-bla-for-tabelecleucel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv-ptld/ (July 25, 2025 – slightly different date than text, but confirms the event)
- Patient Population:
* Claim: Eligible patients had EBV-positive PTLD and prior solid organ transplant (kidney, liver, heart, lung, pancreas, or small bowel) or prior HCT.
* Verification: This aligns with the ClinicalTrials.gov entry for the ALLELE study: https://clinicaltrials.gov/study/NCT05384484 (last updated Jan 7, 2026 – matches text).
- Adverse Events:
* Claim: 62.7% of patients had treatment-emergent serious adverse effects (SAEs), including 8.0% related to treatment. No tumor flare, infusion reactions, CRS, bone marrow rejection, neurotoxicity, immunogenicity, or infectious disease transmission. 11.5% of HCT patients experienced graft-versus-host-disease; 6.1% of solid organ transplant patients had bone marrow or organ rejection. none of these events were treatment-related.
* Verification: This information is based on findings presented at the european Society for Blood and Marrow Transplantation Meeting (March 30-April 2,2025). The abstract (OS17-03) is cited. Unluckily, without access to the full abstract, it’s difficult to fully verify these specific percentages. However, the general findings are consistent with reports about tab-cel’s safety profile.* https://www.atarabio.com/news-releases/news-release-details/atara-biotherapeutics-provides-regulatory-and (January 12, 2026 – matches text) mentions positive safety data.
4.